Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
11 April 2024 - 9:30PM
Business Wire
The Executive Officers of Zai Lab Limited (NASDAQ: ZLAB; HKEX:
9688), Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart,
Yajing Chen, F. Ty Edmondson, as well as Jonathan Wang, today
announced that they have each agreed that they do not anticipate
selling any shares in Zai Lab through the remainder of 2024, except
for any shares in existing Rule 10b5-1 plans that are currently
effective or to cover tax obligations associated with the vesting
of equity awards.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative,
research-based, commercial-stage biopharmaceutical company based in
China and the United States. We are focused on discovering,
developing, and commercializing innovative products that address
medical conditions with significant unmet needs in the areas of
oncology, autoimmune disorders, infectious disease, and
neuroscience. Our goal is to leverage our competencies and
resources to positively impact human health in China and
worldwide.
For additional information about Zai Lab, including our
products, business activities and partnerships, research, and other
events or developments, please visit www.zailaboratory.com or
follow us at www.twitter.com/ZaiLab_Global.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240411061563/en/
For more information, please contact: Investor
Relations: Christine Chiou / Lina Zhang +1 (917) 886-6929 / +86
136 8257 6943 christine.chiou1@zailaboratory.com /
lina.zhang@zailaboratory.com
Media: Shaun Maccoun / Xiaoyu Chen +1 (415) 317-7255 /
+86 185 0015 5011 shaun.maccoun@zailaboratory.com /
xiaoyu.chen@zailaboratory.com
Zai Lab (NASDAQ:ZLAB)
Historical Stock Chart
From Apr 2024 to May 2024
Zai Lab (NASDAQ:ZLAB)
Historical Stock Chart
From May 2023 to May 2024